X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18) 18
index medicus (18) 18
rheumatology (16) 16
arthritis, rheumatoid - drug therapy (14) 14
rheumatoid arthritis (13) 13
female (12) 12
male (12) 12
middle aged (10) 10
antirheumatic agents - administration & dosage (9) 9
infliximab (9) 9
methotrexate (8) 8
aged (7) 7
tnf inhibitors (7) 7
adalimumab (6) 6
antirheumatic agents - therapeutic use (6) 6
drug dosages (6) 6
severity of illness index (6) 6
treatment outcome (6) 6
tumor necrosis factor-alpha - antagonists & inhibitors (6) 6
tumor necrosis factor-tnf (6) 6
etanercept (5) 5
quality of life (5) 5
studies (5) 5
anti-tnf (4) 4
arthritis, rheumatoid - blood (4) 4
cohort studies (4) 4
disease-activity (4) 4
patients (4) 4
therapy (4) 4
abridged index medicus (3) 3
american-college (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
arthritis, rheumatoid - diagnostic imaging (3) 3
clinical medicine (3) 3
discontinuation (3) 3
disease activity (3) 3
disease control (3) 3
disease progression (3) 3
dose reduction (3) 3
dose-response relationship, drug (3) 3
drug administration schedule (3) 3
drug therapy (3) 3
follow-up studies (3) 3
joint damage (3) 3
malignancies (3) 3
medicine, general & internal (3) 3
metaanalysis (3) 3
randomized controlled trials as topic (3) 3
randomized controlled-trial (3) 3
recurrence (3) 3
remission (3) 3
rheumatoid-arthritis (3) 3
risk (3) 3
strategies (3) 3
tapering (3) 3
time factors (3) 3
usage (3) 3
withdrawal (3) 3
activity score (2) 2
adalimumab - administration & dosage (2) 2
adult (2) 2
antibodies (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - blood (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antirheumatic agents - blood (2) 2
antirheumatic agents - economics (2) 2
arthritis (2) 2
arthritis, rheumatoid - diagnosis (2) 2
biomarkers - blood (2) 2
care and treatment (2) 2
clinical trials (2) 2
clinical-practice (2) 2
clinically important difference (2) 2
college-of-rheumatology (2) 2
cost analysis (2) 2
cost-benefit analysis (2) 2
costs (2) 2
definition (2) 2
design (2) 2
diagnosis (2) 2
dmards (2) 2
dosage and administration (2) 2
dose-response relationship (2) 2
double-blind (2) 2
economic evaluations (2) 2
efficacy (2) 2
etanercept - administration & dosage (2) 2
immunoglobulin g - administration & dosage (2) 2
improvement (2) 2
longitudinal studies (2) 2
low-dose etanercept (2) 2
orthopedics (2) 2
orthopedics and sports medicine (2) 2
prospective studies (2) 2
radiographic progression (2) 2
randomised controlled trial (2) 2
receptors, tumor necrosis factor - administration & dosage (2) 2
remission induction (2) 2
reproducibility of results (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2019, Volume 78, Issue 1, pp. 141 - 142
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2014, Volume 73, Issue 1, pp. e4 - E4
  [...]we would suggest to expand your search by using other databases (Embase, Cochrane Central Register of Controlled Trials, trial registries) and more... 
Amyloidosis | COHORT | RHEUMATOLOGY | Analgesics | RHEUMATOID-ARTHRITIS PATIENTS | Adult Onset Still's Disease | Biological Products - administration & dosage | Withholding Treatment | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - drug therapy | Humans | Studies
Journal Article
Nederlands Tijdschrift voor Geneeskunde, ISSN 0028-2162, 2018, Volume 162, Issue 3
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 11/2016, Volume 75, Issue 11, pp. 1939 - 1944
BACKGROUND: A disease activity-guided dose optimisation strategy of adalimumab or etanercept (TNFi (tumour necrosis factor inhibitors)) has shown to be... 
Journal Article
Journal Article
Journal Article
Pharmaceutisch Weekblad, ISSN 0031-6911, 11/2013, Volume 148, Issue 48, pp. 16 - 19
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10, pp. 1716 - 1722
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10, pp. 1716 - 1722
Objective T umour necrosis factor inhibitors (TN Fi) are effective in rheumatoid arthritis (RA), but disadvantages include adverse events (AEs) and high costs.... 
Immunology | Rheumatology | Biochemistry, Genetics and Molecular Biology(all) | Immunology and Allergy
Journal Article
Trials, ISSN 1745-6215, 12/2020, Volume 21, Issue 1, pp. 1 - 12
Abstract Background Tumour necrosis factor inhibitors (TNFi) are effective in the treatment of patients with spondyloarthritis (SpA), including psoriatic... 
Tapering | TNF inhibitors | Spondyloarthritis | Randomised controlled trial | Psoriatic arthritis | Dose reduction
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2014, Volume 73, Issue 1, pp. e4 - e4
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2019, Volume 78, Issue 1, pp. 141 - 142
In the extension phase, both groups were treated according to a treat-to-target protocol: tapering was recommended in case of a stable low disease activity, at... 
economic evaluations | DMARDs (biologic) | rheumatoid arthritis | anti-TNF | RHEUMATOLOGY | Tumor necrosis factor-TNF | TNF inhibitors | Cost analysis | Patients | Rheumatoid arthritis | Quality of life
Journal Article
Journal Article